Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MEDI1814 for IV injection
MEDI1814 · 1 trial · 2 indications
Tolerability measured by participant withdrawal for an adverse event from randomization through end of study
| Arm | Type | Description |
|---|---|---|
| MEDI1814 IV | EXPERIMENTAL | Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg. |
| IV Placebo | PLACEBO_COMPARATOR | Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg. |
| MEDI1814 Sub Cutaneous Injection | EXPERIMENTAL | 2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort |
| Subcutaneous Placebo | PLACEBO_COMPARATOR | 2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort |
| Name | Type | Description |
|---|---|---|
| MEDI1814 for IV injection | BIOLOGICAL | Monoclonal antibody for IV Injection |
| MEDI1814 for Subcutaneous Injection | BIOLOGICAL | Monoclonal antibody for subcutaneous injection |
| IV Placebo | BIOLOGICAL | Placebo for IV injection |
| Placebo for Subcutaneous Injection | BIOLOGICAL | Subcutaneous Placebo Injection |
Inclusion Criteria Male and female (non child bearing potential) subjects Mild-moderate Alzheimer's Disease Exclusion Criteria History or evidence of significant autoimmune disease Presence of psychiatric disorder which would affect completion of the study Current serious or unstable clinically imp...
MEDI1814 is an investigational monoclonal antibody being studied for the treatment of mild to moderate Alzheimer's disease. It was evaluated in a Phase 1 clinical trial that enrolled 77 participants, including patients with mild to moderate Alzheimer's disease and healthy elderly volunteers. The study has been completed.
MEDI1814 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored the Phase 1 study of MEDI1814 in mild to moderate Alzheimer's disease.
MEDI1814 is in Phase 1 clinical development. The single Phase 1 trial, NCT02036645, has been completed. MEDI1814 is investigational and has not been approved by the FDA for any indication.
MEDI1814 was studied in one Phase 1 clinical trial, NCT02036645, titled a single ascending dose and multiple ascending dose study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of MEDI1814 in subjects with mild to moderate Alzheimer's disease. The trial enrolled 77 participants in the United States and is completed.
Yes. MEDI1814 for IV injection is an alternative name for MEDI1814, the investigational monoclonal antibody developed by AstraZeneca for mild to moderate Alzheimer's disease. Both names refer to the same drug candidate.
MEDI1814 is a monoclonal antibody. It is being developed as an investigational therapy for mild to moderate Alzheimer's disease and was tested in a Phase 1 trial that included both patients with Alzheimer's disease and healthy elderly volunteers.